Evidence map›Paper›PMID 26883028›Full record

ArticleGlycoconjugate journal2016

Immunization of A4galt-deficient mice with glycosphingolipids from renal cell cancers resulted in the generation of anti-sulfoglycolipid monoclonal antibodies.

Reiko Ando, Noriyo Tokuda, Tokunori Yamamoto, Kazutaka Ikeda, Noboru Hashimoto, Ryo Taguchi, Xiaoen Fan, Keiko Furukawa, Yukio Niimura, Akemi Suzuki and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Glycoconjugate journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Reiko AndoDepartment of Biochemistry II, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-0065, Japan.
Noriyo TokudaDepartment of Biochemistry II, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-0065, Japan.
Tokunori YamamotoDepartment of Urology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-0065, Japan.
Kazutaka IkedaIMS, RIKEN Center for Integrative Medical Sciences, 1-7-22, Suehiro, Tsurumi-ku, Yokohama, 230-0045, Japan.
Noboru HashimotoDepartment of Biochemistry II, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-0065, Japan.
Ryo TaguchiDepartment of Biomedical Sciences, Chubu University College of Life and Health Sciences, 1200 Matsumoto, Kasugai, Aichi, 487-8501, Japan.
Xiaoen FanDepartment of Biochemistry II, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-0065, Japan.
Keiko FurukawaDepartment of Biochemistry II, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-0065, Japan.
Yukio NiimuraResearch Center of Biomedical Analysis and Radioisotope, Teikyo University School of Medicine, 2-11-1, Kuga, Itabashi-ku, Tokyo, 173-8605, Japan.
Akemi SuzukiInstitute of Glycoscience, Tokai University, 4-1-1 Kitakaname, Hiratsuka, Kanagawa, 259-1292, Japan.
Momokazu GotoDepartment of Urology, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-0065, Japan.
Koichi FurukawaDepartment of Biochemistry II, Nagoya University Graduate School of Medicine, 65 Tsurumai, Showa-ku, Nagoya, 466-0065, Japan. koichi@med.nagoya-u.ac.jp.
Nagoya University · JPChubu University · JPRIKEN Center for Integrative Medical Sciences · JPTeikyo University · JPTokai University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we immunized Gb3/CD77 synthase gene (A4galt) knockout (KO) mice with glycosphingolipids (GSLs) extracted from 3 renal cell cancer (RCC) cell lines to raise monoclonal antibodies (mAbs) reactive with globo-series GSLs specifically expressed in RCCs. Although a number of mAbs reactive with globo-series GSLs were generated, they reacted with both RCC cell lines and normal kidney cells. When we analyzed recognized antigens by mAbs that were specifically reactive with RCC, but not with normal kidney cells at least on the cell surface, many of them turned out to be reactive with sulfoglycolipids. Eight out of 11 RCC-specific mAbs were reactive with SM2 alone, and the other 3 mAbs were more broadly reactive with sulfated glycolipids, i.e. SM3 and SM4 as well as SM2. In the immunohistochemistry, these anti-sulfoglycolipids mAbs showed RCC-specific reaction, with no or minimal reaction with adjacent normal tissues. Thus, immunization of A4galt KO mice with RCC-derived GSLs resulted in the generation of anti sulfated GSL mAbs, and these mAbs may be applicable for the therapeutics for RCC patients.

Indexed as

ImmunizationKidney NeoplasmsAnimalsAntibodies, Monoclonal, Murine-DerivedAntibodies, NeoplasmCell Line, TumorGalactosyltransferasesGlycolipidsHumansMiceMice, Inbred BALB CMice, KnockoutMice, NudeAntibodies, Monoclonal, Murine-DerivedAntibodies, NeoplasmGalactosyltransferasesGlycolipidssulfoglycolipidsUDP-galactose-lactosylceramide alpha 1-4-galactosyltransferaseA4galtKidneyMonoclonal antibodyRenal cell cancerSulfoglycolipid

Identifiers

PMID26883028
OpenAlexW2284484479

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.